期刊文献+

云南白药对牙龈卟啉单胞菌诱导骨破坏中RANK/RANKL/OPG系统的影响 被引量:3

Effects of Yunnan Baiyao on RANK/RANKL/OPG system in porphyromonas gingivalis induced bone destruction
下载PDF
导出
摘要 目的建立昆明小鼠头颅骨接种牙龈卟啉单胞菌(Pg)的动物模型,客观评价云南白药对Pg诱导的骨破坏中核因子-κB受体活化因子(RANK)/RANK配体(RANKL)/骨保护素(OPG)系统的影响。方法 72只雄性昆明小鼠分为模型组、云南白药治疗组、对照组。模型组和云南白药治疗组在小鼠两耳中间颅顶至枕部骨的骨上接种Pg,同时云南白药治疗组在建模的当天开始给予云南白药灌胃。在建模的第5、8、14天各组分别处死8只小鼠。检测头颅骨中破骨细胞的含量及头颅骨中RANKL、OPG mRNA的表达。结果在术后3个时间点模型组的破骨细胞数目及头颅骨中RANKL mRNA的表达均明显高于云南白药治疗组(P<0.05);模型组、云南白药治疗组也明显高于对照组(P<0.05)。OPG mRNA的表达在各组之间进行比较则发现在术后3个时间点中云南白药治疗组均明显高于模型组和对照组(P<0.05);而在第5天模型组低于对照组(P<0.05),第8、14天模型组高于对照组(P<0.05)。结论云南白药可下调RANKL mRNA的表达,上调OPG mRNA的表达,以抑制破骨细胞的形成,提高骨的修复能力,从而抑制骨的吸收,促进骨的修复。 Objective To detect the effects of Yunnan Baiyao on receptor activator of NF-κB(RANK)/receptor activator of NF-κB ligand(RANKL)/osteoprotegerin(OPG) system by means of animal model that use Porphyromonas gingivalis(Pg) induce cal-varial to induce bone destroy .Methods Seventy-two male Kunming mouses were selected and randomly divided into model group , Yunnan Baiyao treatment group and control group .The animals of model group and Yunnan Baiyao treatment group were inoculated Pg at the midline of the scalp between the ears and the animals of the Yunnan Baiyao treatment group gastric perfusion Yunnan Baiyao after them inoculated Pg .Mouses were killed at 5 ,8 and 14 days after inoculation .For each data point ,killed eight mice(n=8) ,then detected the number of osteoclast of the calvaria and the change of RANKL mRNA ,OPGm RNA express .Results On the 5th ,8th and 14th day the number of osteoclast and the content of RANKL mRNA expression in the model group apparently higher than in the Yunnan Baiyao treatment group(P&lt;0 .05) ,two groups also apparently higher than in the control group(P&lt;0 .05) .A-bout OPG mRNA expression on the 5th ,8th and 14th day in the Yunnan Baiyao treatment group apparently higher than in the con-trol group and model group(P&lt;0 .05) ,but on the 5th day the model group lower than the control group(P&lt;0 .05) and on the 8th , 14 day the model group higher than the control group(P&lt;0 .05) .Conclusion Yunnan Baiyao can cut regulation RANKL mRNA expression and raise regulation OPG mRNA expression to inhibit bone destruction and improve bone repair and inhibiting osteoclast product so as to inhibit bone destroy and improve bone repair .
出处 《重庆医学》 CAS CSCD 北大核心 2014年第21期2739-2742,共4页 Chongqing medicine
基金 国家自然科学基金项目(81060086) 云南省自然科学基金项目(2010CD215)
关键词 云南白药 牙龈卟啉单胞菌 骨保护素 核因子-ΚB受体活化因子配体 破骨细胞 Yunnan Baiyao porphyromonas gingivalis osteoprotegerin ligand of receptor activator of NK-κB osteoclast
  • 相关文献

参考文献17

  • 1于世凤,史凤芹,章魁华.骨质疏松症与颌骨[J].现代口腔医学杂志,1995,9(1):38-39. 被引量:7
  • 2Parfitt to the Relate A. The coupling of bone formation to bone resorp- critical analysis of the concept and of its relevance pathogenesis of osteoporosis[J]. Metab Bone Dis Res,1982,4(1) :1-6.
  • 3Suda T, Takahashi N, Udaqawa N, et al. Modulation of osteoclast differentiation and function by the new mem- bers of the tumor necrosis factor receptor and ligand ram-ilies[J]. Endocrine Rev, 1999,20(3) : 345-357.
  • 4蔡锡麟.云南白药的药理研究[J].中成药研究,1982(8):37.
  • 5王彦亭.云南白药主要成分的骨形成作用研究[J].昆明医学院学报,2008,6(12):12—15.
  • 6He H, Liu R,Desta T, et al. Diabetes causes decreased os- teoclastogenesis, reduced bone formation, and enhanced apoptosis of osteoblastic cell in bacteria stimulated bone loss[J]. Endocrinology, 2004,14:5 ( 1 ) : 447-452.
  • 7Gaspersic R,Stiblar Martincic D, Skaleric U. Influence of restraint stress on ligature-induced periodontitis in rats [J]. Eur J Oral Sci,2002,110(2) :125-129.
  • 8Mundy GR. Local factors in bone remodeling[J]. Recent Prog Horn Res,1989,45:507-527.
  • 9Khosla S. The OPG/RANKL/RANK system[J]. Endo- crinology, 2001,142 (12) : 5050-5055.
  • 10Jones DH ,Kong YY, Penninger JM. Role of RANKL and RANK in bone loss and arthritis[J]. Ann Rheum Dis, 2002,61 (2) : 32-39.

二级参考文献10

共引文献37

同被引文献34

  • 1李朵,魏启幼.骨微结构与骨质疏松性骨折[J].中国骨质疏松杂志,2004,10(4):519-522. 被引量:12
  • 2中国药典,一部[S].2010:263.
  • 3DE MARTINIS M, DI BENEDETTO M C, MENGOLI L P, et al. Senile osteoporosis: is it an immune-mediated disease [J]. InfRes, 2006, 55(10): 399-404.
  • 4TEITELBAUM S L. Osteoclasts: what do they do and how do they do it [J]. Am J Pathol, 2007, 170(2): 427-435.
  • 5NAKAMURA M, UDAGAWA N, MATSUURA S, et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption [J]. Endocrinology, 2003, 144(12): 5441-5449.
  • 6TELLA S H, GALLAGHER J C. Prevention and treatment of postmenopausal osteoporosis [J]. J Steroid Biochem Mol Biol, 2014(142): 155-170.
  • 7WHITESIDE L A. Surgical technique: Transfer of the anterior portion of the gluteus maximus muscle for abductor deficiency of the hip [J]. Clin Orthop Relat Res, 2012, 470(2): 503-510.
  • 8WATERS K M, RICKARD D J, RIGGS B L, et al. Estrogen regulation of human osteo-blast function is determined by the stage of differentiation andthe estrogen receptor isoform [J]. Cell Biochem, 2001, 83(3): 448-462.
  • 9LIHUAN C, RONGFA B, JENNIFER I, et al. Estrogen receptor beta modulatessynthesis of bone matrix proteins in human osteoblast-like MG63 cells [J]. J Cell Biochem, 2003, 89(1): 152-164.
  • 10WANG Y, LI L Z, ZHANG Y L, et al. LC, a novel estrone-rhein hybrid compound, concurrently stimulates osteoprotegerin and inhibits receptor activator ofNF-κB ligand (RANKL) and interleukin-6 production by human osteoblastic cells [J]. Mol Cell Endocrinol, 2011,337(1/2): 43-51.

引证文献3

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部